PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34260122-2 2021 BACKGROUND: Dexmedetomidine is a potent and highly selective alpha-2 adrenoceptor agonist with sympatholytic, sedative, anxiolytic, and analgesic properties. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 61-68 34767940-3 2021 Dexmedetomidine, an alpha2- adrenergic agonist, differs from GABA-ergic sedatives both mechanistically and clinically as it allows easy arousability from deep sedation with less cognitive side-effects. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 20-26 34736995-15 2021 Interestingly, we identified dexmedetomidine (DMM), an alpha-2 adrenergic agonist, inhibiting the secretion of infectious viral progeny by approx. Dexmedetomidine 29-44 glycoprotein hormone subunit alpha 2 Homo sapiens 55-62 34736995-15 2021 Interestingly, we identified dexmedetomidine (DMM), an alpha-2 adrenergic agonist, inhibiting the secretion of infectious viral progeny by approx. Dexmedetomidine 46-49 glycoprotein hormone subunit alpha 2 Homo sapiens 55-62 34640590-10 2021 Therefore, counterintuitively, antihypertensive agents such as beta-blockers or alpha-2 adrenergic agonists (clonidine, dexmedetomidine) are useful. Dexmedetomidine 120-135 glycoprotein hormone subunit alpha 2 Homo sapiens 80-87 34987573-1 2021 Background: Dexmedetomidine is a selective alpha-2 agonist commonly used for sedation that has been used in obstetric anesthesia for multimodal labor analgesia, postcesarean delivery analgesia, and perioperative shivering. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 43-50 34825041-1 2021 Dexmedetomidine is an alpha-2 agonist sedative and analgesic used in anesthesia practice, and it has become more prevalent in the critically ill patients requiring short-term mechanical ventilation. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 22-29 34374168-2 2022 A variety of interventions can be utilized to improve compliance with NIV, including medications such as dexmedetomidine, an alpha-2 agonist with sedative and analgesic effects.9 Current guidelines recommend the use of a non-benzodiazepine sedative such as propofol or dexmedetomidine in critically ill, mechanically ventilated adults, as these medications may improve delirium, ICU length of stay, and duration of mechanical ventilation.10. Dexmedetomidine 105-120 glycoprotein hormone subunit alpha 2 Homo sapiens 125-132 34510502-3 2022 Such is the case of dexmedetomidine, a selective alpha-2 adrenergic agonist used in the intensive care unit (ICU) as a sedative agent. Dexmedetomidine 20-35 glycoprotein hormone subunit alpha 2 Homo sapiens 49-56 34449500-1 2021 BACKGROUND: Dexmedetomidine (Dexm), a selective alpha-2 adrenoceptor agonist, and dexamethasone (Dexa), a very potent and highly selective glucocorticoid, have both been proven effectively to prolong the duration of local anesthetics (LA) in regional anesthesia. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 48-55 34449500-1 2021 BACKGROUND: Dexmedetomidine (Dexm), a selective alpha-2 adrenoceptor agonist, and dexamethasone (Dexa), a very potent and highly selective glucocorticoid, have both been proven effectively to prolong the duration of local anesthetics (LA) in regional anesthesia. Dexmedetomidine 29-33 glycoprotein hormone subunit alpha 2 Homo sapiens 48-55 34546899-2 2021 Dexmedetomidine (DEX), a central alpha-2 agonist, is increasingly being used, and intensive care unit (ICU) data demonstrate improved outcomes in patients with respiratory failure. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 33-40 34546899-2 2021 Dexmedetomidine (DEX), a central alpha-2 agonist, is increasingly being used, and intensive care unit (ICU) data demonstrate improved outcomes in patients with respiratory failure. Dexmedetomidine 17-20 glycoprotein hormone subunit alpha 2 Homo sapiens 33-40 34306020-2 2021 Our previous studies showing the application of dexmedetomidine, an alpha2-AR agonist, can significantly improve maternal sleep, as well as relieve and reduce the incidence of PDS. Dexmedetomidine 48-63 glycoprotein hormone subunit alpha 2 Homo sapiens 68-74 34322087-16 2021 Conclusions: PERM is an immune-mediated disorder, but dexmedetomidine, a highly selective alpha2-adrenergic agonist, may alleviate paroxysmal symptoms by decreasing noradrenergic neuronal activity, resulting in attenuation of antibody-mediated disinhibited increased motor and sympathetic activity. Dexmedetomidine 54-69 glycoprotein hormone subunit alpha 2 Homo sapiens 90-96 34321684-2 2021 This study aims to compare the effect of intraperitoneal instillation of bupivacaine with alpha-2 agonists (dexmedetomidine and clonidine) for postoperative analgesia. Dexmedetomidine 108-123 glycoprotein hormone subunit alpha 2 Homo sapiens 90-97 34349335-3 2020 Dexmedetomidine is a newer and potent alpha-2 receptor agonist which has 10 times higher selectivity for alpha-2 receptors as compared to clonidine, So far, very few studies have been undertaken to compare the efficacy of clonidine and dexmedetomidine to provide and prolong postoperative analgesia, especially with the use of ultrasound for nerve localization. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 105-112 34214520-1 2022 INTRODUCTION AND OBJECTIVE: Dexmedetomidine are a potent adrenergic alpha-2 agonist, and analgesic, sedative, anxiolytic and sympatholytic. Dexmedetomidine 28-43 glycoprotein hormone subunit alpha 2 Homo sapiens 68-75 34202110-1 2021 Dexmedetomidine, selective alpha2-adrenergic agonist dexmedetomidine, has been widely used clinically for sedation and anesthesia. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 27-33 34202110-1 2021 Dexmedetomidine, selective alpha2-adrenergic agonist dexmedetomidine, has been widely used clinically for sedation and anesthesia. Dexmedetomidine 53-68 glycoprotein hormone subunit alpha 2 Homo sapiens 27-33 32621112-3 2021 Dexmedetomidine is alpha-2 adrenoceptor highly selective agonist approved for procedural sedation use. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 19-26 34249955-1 2021 Background: Although clonidine and dexmedetomidine are used as alpha-2 agonists to improve the quality and duration of blockade induced by local anesthetics, no study has been reported to compare their associated adverse events in local anesthesia. Dexmedetomidine 35-50 glycoprotein hormone subunit alpha 2 Homo sapiens 63-70 35046398-2 2022 Dexmedetomidine, a highly selective alpha2-adrenergic agonist, is widely used in perioperative settings for analgesia and sedation. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 36-42 35421323-1 2022 Dexmedetomidine is a selective alpha-2 adrenergic agonist utilized for sedation in critically ill patients.1 We present the case of a morbidly obese critically ill patient who experienced profound hyperthermia, with a maximum temperature of 41.4 C, hours after starting a dexmedetomidine infusion that was otherwise not explained by her clinical diagnoses. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 31-38 35394159-2 2022 Here we report two single-blinded, placebo-controlled intravenous (IV) drug application studies in which we pharmacologically modified SNS activity with epinephrine (study 1) as well as dexmedetomidine (alpha2-agonist) and yohimbine (alpha2-antagonist) (study 2). Dexmedetomidine 186-201 glycoprotein hormone subunit alpha 2 Homo sapiens 203-209 35511098-6 2022 This understanding of the brain functions subsumed by the LC has, in turn, led to the most recent development in the use of dexmedetomidine, an alpha-2 adrenergic agonist, to treat agitation in patients with bipolar disorder. Dexmedetomidine 124-139 glycoprotein hormone subunit alpha 2 Homo sapiens 144-151 35097088-2 2022 The latter condition, a medical emergency, was effectively treated with medical treatment and dexmedetomidine, a versatile and highly selective short-acting alpha-2 adrenergic agonist with sedative-hypnotic and anxiolytic effects. Dexmedetomidine 94-109 glycoprotein hormone subunit alpha 2 Homo sapiens 157-164 33906497-3 2021 Despite being used primarily as a sedative over the past 20 years, dexmedetomidine, a centrally acting alpha2-agonist, possesses analgaesic properties, though its use has been limited by its well-described cardiovascular suppressive effects. Dexmedetomidine 67-82 glycoprotein hormone subunit alpha 2 Homo sapiens 103-109 35422557-1 2021 Context: Dexmedetomidine, an alpha2-agonist, has been studied widely as an adjuvant to local anesthetics in regional anesthesia techniques to enhance the quality and duration of analgesia (DOA). Dexmedetomidine 9-24 glycoprotein hormone subunit alpha 2 Homo sapiens 29-35 33688441-1 2021 Dexmedetomidine is an alpha2-adrenergic used as an adjunct therapy for sedation in the intensive care unit. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 22-28 33395103-7 2021 In development is an intranasal formulation for olanzapine (a well characterized atypical antipsychotic already approved to treat agitation) and a sublingual film for dexmedetomidine (an alpha2-adrenergic agonist used as an anesthetic and now being repurposed). Dexmedetomidine 167-182 glycoprotein hormone subunit alpha 2 Homo sapiens 187-193 32434291-1 2021 Background: Dexmedetomidine, an alpha-2 agonist, has been used for attenuation of hemodynamic response to laryngoscopy, but not through the nebulized route. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 32-39 33450087-3 2021 Experimental and clinical studies support the notion that the alpha2 -adrenoceptor agonists, dexmedetomidine and clonidine, mitigate sympathetic and inflammatory overactivity in sepsis and cardiac surgery requiring cardiopulmonary bypass. Dexmedetomidine 93-108 glycoprotein hormone subunit alpha 2 Homo sapiens 62-68 32696258-1 2021 PURPOSE: To evaluate whether use of dexmedetomidine, a centrally acting alpha2 adrenergic agonist, reduces opioid consumption in PSF. Dexmedetomidine 36-51 glycoprotein hormone subunit alpha 2 Homo sapiens 72-78 33421200-1 2021 BACKGROUND: Dexmedetomidine is a centrally-acting alpha-2 receptor agonist used to maintain light analgosedation in mechanically ventilated adults. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 50-57 33693047-2 2020 Dexmedetomidine is a sedative agent that operates via the alpha2 adrenergic agonist, which provides sleep-like sedation with little respiratory suppression. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 58-64 33423824-1 2021 BACKGROUND: Dexmedetomidine (DEX) is an alpha-2 adrenergic drug used for short sedation and as an alternative to diazepam (DZP) in the treatment of alcohol withdrawal syndrome (AWS). Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 40-47 33423824-1 2021 BACKGROUND: Dexmedetomidine (DEX) is an alpha-2 adrenergic drug used for short sedation and as an alternative to diazepam (DZP) in the treatment of alcohol withdrawal syndrome (AWS). Dexmedetomidine 29-32 glycoprotein hormone subunit alpha 2 Homo sapiens 40-47 33239930-2 2020 Based on the principles of PCA, we developed Patient-Controlled Sleep (PCSL) for chronic intractable insomnia where the traditional analgesics in PCA were replaced with dexmedetomidine (Dex), an alpha-2 agonist widely used for premedication, sedation, anxiolysis and analgesia. Dexmedetomidine 169-184 glycoprotein hormone subunit alpha 2 Homo sapiens 195-202 33841540-5 2020 In addition to being the state-of-the-art treatment including volume load and vasopressor, use of alpha-2 agonists e.g. dexmedetomidine (DXM) in septic shock can reduce vasopressors needed to restore adequate blood pressure. Dexmedetomidine 120-135 glycoprotein hormone subunit alpha 2 Homo sapiens 98-105 33118274-1 2021 Dexmedetomidine, an alpha2 -agonist, is used in the PICU for its sedative properties as it minimally affects respiratory status. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 20-26 32501525-1 2020 OBJECTIVE: To evaluate the efficacy and safety of sedation with dexmedetomidine, a highly selective alpha2-agonist with sedative effect, for EEG recording in children with behavioral disorders. Dexmedetomidine 64-79 glycoprotein hormone subunit alpha 2 Homo sapiens 100-106 33633422-5 2020 Dexmedetomidine is an alpha-2-adrenergic agonist used as additive for regional nerve block. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 22-29 33060552-1 2022 Dexmedetomidine (DEX), an alpha2-adrenergic agonist, has been widely used for anesthesia, pain control, and intensive care unit sedation. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 26-32 33060552-1 2022 Dexmedetomidine (DEX), an alpha2-adrenergic agonist, has been widely used for anesthesia, pain control, and intensive care unit sedation. Dexmedetomidine 17-20 glycoprotein hormone subunit alpha 2 Homo sapiens 26-32 33072186-1 2020 Background: Dexmedetomidine, an alpha2 agonist, has well-known anesthetic and analgesic-sparing effects. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 32-38 32990204-2 2020 Dexmedetomidine, a highly selective alpha2 agonist, has been shown to prevent emergence delirium in the perioperative setting; however, recommendations for best practice regarding use of this medication are not widely available. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 36-42 32822215-5 2020 Intra-arterial infusion of phenylephrine (alpha1-agonist) and dexmedetomidine (alpha2-agonist) were used to induce vasoconstriction: ((FVCwith drug-FVCpre-drug)/FVCpre-drugx100%). Dexmedetomidine 62-77 glycoprotein hormone subunit alpha 2 Homo sapiens 79-85 33841540-5 2020 In addition to being the state-of-the-art treatment including volume load and vasopressor, use of alpha-2 agonists e.g. dexmedetomidine (DXM) in septic shock can reduce vasopressors needed to restore adequate blood pressure. Dexmedetomidine 137-140 glycoprotein hormone subunit alpha 2 Homo sapiens 98-105 32801534-2 2020 Dexmedetomidine, an alpha-2 adrenoceptor agonist, has both sedative and analgesic properties with minimal cardiorespiratory effects and has been used primarily for its sedative properties in oral and maxillofacial surgery. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 20-27 32984835-10 2020 Dexmedetomidine, a centrally acting alpha-2 agonist, may alter hypothalamic temperature regulation through disturbances in neurotransmitter expression and metabolism. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 36-43 32571181-1 2020 BACKGROUND: Dexmedetomidine and clonidine are the most extensively studied drugs for shivering treatment, because alpha2-adrenergic agonists can reduce the shivering threshold. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 114-120 32819417-3 2020 The use of alpha-2-agonists such as clonidine and dexmedetomidine in newborn infants is more recent, and they might be prescribed to reduce the total amount of opioids which are thought to have more side effects. Dexmedetomidine 50-65 glycoprotein hormone subunit alpha 2 Homo sapiens 11-18 32678054-2 2020 Experimental data suggest that central alpha2-agonists like dexmedetomidine (DEX) increase vasopressor responsiveness and reduce catecholamine requirements in septic shock. Dexmedetomidine 60-75 glycoprotein hormone subunit alpha 2 Homo sapiens 39-45 32678054-2 2020 Experimental data suggest that central alpha2-agonists like dexmedetomidine (DEX) increase vasopressor responsiveness and reduce catecholamine requirements in septic shock. Dexmedetomidine 77-80 glycoprotein hormone subunit alpha 2 Homo sapiens 39-45 32297286-1 2020 INTRODUCTION: Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist without any effect on the GABA receptor. Dexmedetomidine 14-29 glycoprotein hormone subunit alpha 2 Homo sapiens 52-59 32476028-7 2020 alpha2-Agonists such as dexmedetomidine may hold some slight clinical efficacy over agents like propofol, and with respect to oral medications, propranolol might convey some slight advantage compared to others. Dexmedetomidine 24-39 glycoprotein hormone subunit alpha 2 Homo sapiens 0-6 32769293-1 2020 Dexmedetomidine is a centrally acting alpha2 adrenoreceptor agonist used in perioperative medicine due to its sedative, analgesic and sympatholytic properties. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 38-44 32184718-1 2019 Dexmedetomidine (DEX) is a highly selective alpha2-adrenergic agonist with sedative and analgesic properties, with minimal respiratory effects. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 44-50 32334510-1 2020 BACKGROUND: The alpha2-adrenergic agonist dexmedetomidine (DEX) is a sedative and can be used as an adjunct to hypnotics. Dexmedetomidine 42-57 glycoprotein hormone subunit alpha 2 Homo sapiens 16-22 32334510-1 2020 BACKGROUND: The alpha2-adrenergic agonist dexmedetomidine (DEX) is a sedative and can be used as an adjunct to hypnotics. Dexmedetomidine 59-62 glycoprotein hormone subunit alpha 2 Homo sapiens 16-22 32184718-1 2019 Dexmedetomidine (DEX) is a highly selective alpha2-adrenergic agonist with sedative and analgesic properties, with minimal respiratory effects. Dexmedetomidine 17-20 glycoprotein hormone subunit alpha 2 Homo sapiens 44-50 32007239-2 2020 Dexmedetomidine, a selective alpha-2 adrenoreceptor agonist, may reduce AKI because of its sympatholytic and anti-inflammatory effects against ischaemia-reperfusion injury. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 29-36 32031091-2 2020 However, dexmedetomidine an alpha2-adrenergic agent has been found to possess analgesic effect. Dexmedetomidine 9-24 glycoprotein hormone subunit alpha 2 Homo sapiens 28-34 32174664-2 2020 The alpha 2 agonist dexmedetomidine may blunt this stress response, but the optimal dose which will accomplish this without causing hypotension and bradycardia is not well established. Dexmedetomidine 20-35 glycoprotein hormone subunit alpha 2 Homo sapiens 4-11 32461748-2 2020 Dexmedetomidine (DEX) is a selective alpha-2 agonist, with anxiolytic, hypnotic, and analgesic properties, that could play a role in the management of refractory sleep disturbances. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 37-44 32461748-2 2020 Dexmedetomidine (DEX) is a selective alpha-2 agonist, with anxiolytic, hypnotic, and analgesic properties, that could play a role in the management of refractory sleep disturbances. Dexmedetomidine 17-20 glycoprotein hormone subunit alpha 2 Homo sapiens 37-44 33582692-3 2020 Dexmedetomidine, an alpha-2 agonist, augments local anaesthetic action. Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 20-27 31762838-7 2019 A comparison of the procedural details between the first and second sessions identified dexmedetomidine, an alpha-2 adrenergic agonist with a short distribution half-life, as a potential cause of coronary vasospasm seen only in the second session in the same individual. Dexmedetomidine 88-103 glycoprotein hormone subunit alpha 2 Homo sapiens 108-115 30985379-1 2019 BACKGROUND: Dexmedetomidine is a highly selective alpha2-adrenergic agonist, which is increasingly used in pediatric anesthesia and intensive care. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 50-56 31008751-1 2019 BACKGROUND: Dexmedetomidine is a highly selective alpha2-adrenergic agonist, which is increasingly used in pediatric anesthesia and intensive care. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 50-56 31243816-8 2019 Interestingly, the protective effects of DEX were reversed by atipamezole-an alpha 2 adrenal receptor (alpha2 AR) inhibitor, whereas idazoxan-an imidazoline receptor (IR) inhibitor failed to reverse this change. Dexmedetomidine 41-44 glycoprotein hormone subunit alpha 2 Homo sapiens 103-109 31243816-9 2019 In conclusion, DEX attenuated LPS-induced AKI by inhibiting oxidative stress damage and NLRP3 inflammasome activation via regulating the TLR4/NOX4/NF-kappaB pathway, mainly acting on the alpha2 AR rather than IR. Dexmedetomidine 15-18 glycoprotein hormone subunit alpha 2 Homo sapiens 187-193 31762838-8 2019 Since it has been shown that alpha-2 adrenoreceptor-mediated vasoconstriction can involve the coronary circulation, it is thus possible that a stimulation of alpha-2 adrenergic receptors induced by dexmedetomidine caused a coronary vasospasm. Dexmedetomidine 198-213 glycoprotein hormone subunit alpha 2 Homo sapiens 29-36 31762838-8 2019 Since it has been shown that alpha-2 adrenoreceptor-mediated vasoconstriction can involve the coronary circulation, it is thus possible that a stimulation of alpha-2 adrenergic receptors induced by dexmedetomidine caused a coronary vasospasm. Dexmedetomidine 198-213 glycoprotein hormone subunit alpha 2 Homo sapiens 158-165 30826489-4 2019 This study focuses specifically on the role of Sirt1/CD36 in the proliferation of MCF-7 breast cancer cells and also investigates their response to the alpha2-adrenergic agonist dexmedetomidine (Dex). Dexmedetomidine 178-193 glycoprotein hormone subunit alpha 2 Homo sapiens 152-158 30826489-4 2019 This study focuses specifically on the role of Sirt1/CD36 in the proliferation of MCF-7 breast cancer cells and also investigates their response to the alpha2-adrenergic agonist dexmedetomidine (Dex). Dexmedetomidine 195-198 glycoprotein hormone subunit alpha 2 Homo sapiens 152-158 30394918-4 2019 The aim of the present study is to test the hypothesis that switching from sedation with propofol to the alpha-2 agonist dexmedetomidine may decrease norepinephrine doses in septic shock. Dexmedetomidine 121-136 glycoprotein hormone subunit alpha 2 Homo sapiens 105-112 28674865-1 2017 PURPOSE: To report the use of intranasal dexmedetomidine, an alpha2-adrenergic agonist for the acute treatment of refractory adrenergic crisis in patients with familial dysautonomia. Dexmedetomidine 41-56 glycoprotein hormone subunit alpha 2 Homo sapiens 61-67 30394067-2 2019 BACKGROUND: Dexmedetomidine (DEX) is an alpha-2-adrenergic agonist, recently approved by Italian-Medicines-Agency for difficult sedation in pediatrics, but few data exist regarding prolonged infusions in critically-ill children, especially in younger ages. Dexmedetomidine 12-27 glycoprotein hormone subunit alpha 2 Homo sapiens 40-47 30394067-2 2019 BACKGROUND: Dexmedetomidine (DEX) is an alpha-2-adrenergic agonist, recently approved by Italian-Medicines-Agency for difficult sedation in pediatrics, but few data exist regarding prolonged infusions in critically-ill children, especially in younger ages. Dexmedetomidine 29-32 glycoprotein hormone subunit alpha 2 Homo sapiens 40-47 26805677-0 2016 Sedation with alpha2 Agonist Dexmedetomidine During Unilateral Subthalamic Nucleus Deep Brain Stimulation: A Preliminary Report. Dexmedetomidine 29-44 glycoprotein hormone subunit alpha 2 Homo sapiens 14-20 26805677-1 2016 OBJECTIVE: The alpha2 agonist dexmedetomidine (DEX) is an anesthetic agent that can provide sedation and analgesia without respiratory depression or changes in neuronal activity during microrecordings. Dexmedetomidine 47-50 glycoprotein hormone subunit alpha 2 Homo sapiens 15-21 26805677-1 2016 OBJECTIVE: The alpha2 agonist dexmedetomidine (DEX) is an anesthetic agent that can provide sedation and analgesia without respiratory depression or changes in neuronal activity during microrecordings. Dexmedetomidine 30-45 glycoprotein hormone subunit alpha 2 Homo sapiens 15-21 26108432-1 2015 Dexmedetomidine (an alpha-2 adrenergic agonist) sedation is commonly used during subthalamic nucleus (STN) deep-brain stimulation (DBS). Dexmedetomidine 0-15 glycoprotein hormone subunit alpha 2 Homo sapiens 20-27 26671782-1 2015 INTRODUCTION: Dexmedetomidine is an alpha2-agonist recently proposed as a potentially ideal drug for sedation during the surgical treatment of Parkinson"s disease (PD). Dexmedetomidine 14-29 glycoprotein hormone subunit alpha 2 Homo sapiens 36-42 17056959-1 2006 The pharmacologic profile of the alpha-2 agonist dexmedetomidine (Dex) suggests that it may be an ideal sedative drug for deep brain stimulator (DBS) implantation. Dexmedetomidine 49-64 glycoprotein hormone subunit alpha 2 Homo sapiens 33-40 17056959-1 2006 The pharmacologic profile of the alpha-2 agonist dexmedetomidine (Dex) suggests that it may be an ideal sedative drug for deep brain stimulator (DBS) implantation. Dexmedetomidine 66-69 glycoprotein hormone subunit alpha 2 Homo sapiens 33-40